Ruiqiong Zhou

Ruiqiong Zhou

Auto-generated profile, based on publicly available information

Ruiqiong Zhou

Center for Reproductive Medicine, Guangdong Women and Children Hospital , Guangzhou 511400, Guangdong Province

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2021 in Human Reproduction
Verified
Journal Article
Closed access
PDF file
RZRuiqiong Zhou
Ruiqiong Zhou
XZXiqian Zhang
Xiqian Zhang
MDMei Dong
Mei Dong
LHLi Huang
Li Huang
XZXiulan Zhu
Xiulan Zhu
FLFenghua Liu
Fenghua Liu
Is there an association between serum LH levels prior to progesterone administration and live birth rate (LBR) in artificial frozen-thawed embryo transfer (FET) cycles? : Low serum LH levels on the day before progesterone initiation in artificial frozen-thawed blastocyst transfer cycles of ovulatory women are associated with a lower LBR. In artificial FET cycles, exogenous oestrogen and progesterone are administered sequentially to mimic the serum hormone pattern similar to the natural cycle. In oestrogen-only phase, the supplemental oestrogen causes thickening of the endometrium and is sometimes accompanied by a rise in serum LH. However, whether the endogenous LH level in artificial FET cycles is related to clinical outcomes remains unclear. A retrospective cohort study including 3469 artificial frozen-thawed blastocyst transfer cycles was conducted at a tertiary-care academic medical centre between February 2014 and January 2020. A total of 3469 frozen blastocyst transfer cycles were stratified into four groups based on the quartiles of serum LH level before progesterone initiation: <25th percentile (LH < 8.79 mIU/ml), 25–50th percentile (8.79 ≤ LH ≤ 13.91 mIU/ml), 51–75th percentile (13.91 < LH ≤ 20.75 mIU/ml) and >75th percentile (LH > 20.75 mIU/ml). The serum LH level >75th percentile group was considered as the reference group. Patients with polycystic ovarian syndrome or other ovulatory disorders were excluded from the study. We also excluded cycles with an endometrial thickness <7 mm before progesterone initiation and patients with intrauterine adhesions and uterine abnormalities. In order to avoid the interference of BMI, all patients were divided into two categories based on the overweight threshold: BMI <25 kg/m2 and ≥25 kg/m2, and the impacts of serum LH levels on LBR were investigated separately. Univariable and multivariable logistic regression analysis were performed to adjust for potential confounders. EmpowerStats software and R-project were used to build smooth curve fitting models. Compared with the reference group, the implantation rate significantly decreased with low LH levels (<25th percentile) on the day before progesterone initiation (odds ratio [OR] = 0.74; 95% CI, 0.64–0.86; P = 0.001). Accounting for major covariates, low LH levels were associated with a relatively lower LBR (adjusted OR = 0.649; 95% CI, 0.531–0.794; P < 0.001), mainly due to a lower implantation rate, lower clinical pregnancy rate and higher pregnancy loss rate. Moreover, in the patients with BMI <25 kg/m2, low LH was associated with a lower LBR (P < 0.001); while in the overweight subgroup, LBR and LH were not correlated (P = 0.823). The main limitation of this study is its retrospective design. Owing to the relatively small number in the overweight group, the results of the overweight subgroup should be interpreted with caution. The evidence provided in this study shows the importance of serum LH levels on the day before progesterone initiation in patients undergoing artificial FET cycles. Hypothalamic dysfunction may be one of the important causes of a relatively low LH, which is related to impaired pregnancy outcomes. Serum LH levels may be used as one of the clinical indicators to predict pregnancy outcomes. No funding and no competing interest were involved in this study. NA.

14 July 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
RZRuiqiong Zhou
Ruiqiong Zhou
MDMei Dong
Mei Dong
LHLi Huang
Li Huang
SWSonglu Wang
Songlu Wang
ZWZhaoyi Wang
Zhaoyi Wang
FLFenghua Liu
Fenghua Liu
This article has been retracted and replaced. Please see this notice for details: https://doi.org/10.1210/clinem/dgae853.

28 October 2024 in Human Reproduction
Verified
Journal Article
Closed access
PDF file
RZRuiqiong Zhou
Ruiqiong Zhou
ZZZhenghong Zhu
Zhenghong Zhu
MDMei Dong
Mei Dong
ZWZhaoyi Wang
Zhaoyi Wang
LHLi Huang
Li Huang
FLFenghua Liu
Fenghua Liu
Are serum vitamin D levels associated with the incidence of endometrial polyps (EPs) in infertile patients? Serum 25(OH)D levels were nonlinearly correlated with the incidence of EPs in infertile women. EPs are a common condition that may affect the receptivity of the endometrium in women of reproductive age. Vitamin D regulates cell proliferation and differentiation, apoptosis, angiogenesis, anti-inflammation, and immunomodulation, in addition to its well-known functions in balancing calcium and phosphorus. Previous studies have shown that vitamin D concentrations are associated with reproductive outcomes, and that low vitamin D levels are associated with the incidence of colorectal polyps and nasal polyps. There is little evidence regarding the relationship between EPs and serum vitamin D levels. We conducted a cross-sectional study using data from Guangdong Women and Children Hospital from January 2019 to October 2023, enrolling 3107 patients. A total of 3107 infertile patients who underwent hysteroscopy were included in this study; 642 patients had endometrial polyps and 2465 had a normal uterine cavity. Hysteroscopy findings included risk of EPs, polyp size, percentage of multiple polyps, and incidence of chronic endometritis (CE). Serum vitamin D were assessed by measuring total 25(OH)D using chemiluminescence. According to international guideline recommendations for vitamin D deficiency, patients were divided into two groups: the <50 nmol/l group and the ≥50 nmol/l group. Univariable and multivariable logistic regression models, stratified analyses, and smooth curve fitting were used to examine the relationship between serum 25(OH)D levels and risk of EPs. Of all patients, 23.8% (740/3107) were vitamin D deficient (<50 nmol/l). The incidence of EPs was significantly higher in the 25(OH)D < 50 nmol/l group than in the ≥50 nmol/l group (24.9% vs 19.3%; P = 0.001). However, there were no differences in polyp size, proportion of multiple polyps, and presence of CE between the two groups. After controlling for confounders, 25(OH)D ≥ 50 nmol/l (compared with <50 nmol/l) was negatively associated with risk of EPs (adjusted OR, 0.733; 95% CI, 0.598–0.898). Other variables that had an impact on polyp incidence included BMI, type of infertility, CA125, and CD138-positive plasma cells. In addition, a linear regression model between age and serum 25(OH)D levels showed a positive linear association. Subgroup analyses were performed for different age groups, and the risk of EPs was significantly higher in the 25(OH)D < 50 nmol/l group than in the ≥50 nmol/l group, both in the younger subgroup (23.8% vs 19.1%) and in the older subgroup (28.0% vs 19.9%). The smooth curve fitting model showed a nonlinear correlation between 25(OH)D levels and risk of EPs (nonlinear P-value = 0.020), with an optimal threshold of 51.8 nmol/l for 25(OH)D levels. Moreover, subgroup smooth curve fitting models showed a nonlinear correlation between 25(OH)D levels and polyp risk in patients aged <35 years (nonlinear P-value = 0.010), whereas a linear correlation between 25(OH)D levels and polyp risk was found in patients aged ≥35 years (nonlinear P-value = 0.682). Caution should be exercised in interpreting our findings as this is a correlational study and causality cannot be inferred from our results. In addition, because of strict inclusion and exclusion criteria, our results may not be generalizable to unselected populations, including premenopausal women or women of other races. This study demonstrated for the first time that vitamin D deficiency is an independent risk factor for the incidence of EPs in infertile patients. Identifying modifiable risk factors (e.g. vitamin D deficiency) can help in the development of new strategies for treating polyps or to protect against polyp development. Further clinical intervention trials and laboratory studies are needed to evaluate the effect of vitamin D on the development of EPs and to elucidate the mechanisms. The study was funded by the National Natural Science Foundation of China (82101718) and Natural Science Foundation of Guangdong Province, China (2022A1515010776). No competing interest was involved in this study. N/A.


12 March 2026 in Human Reproduction Open
Verified
Journal Article
Open access
RZRuiqiong Zhou
Ruiqiong Zhou
ZWZhaoyi Wang
Zhaoyi Wang
MDMei Dong
Mei Dong
LHLi Huang
Li Huang
NSNianjun Su
Nianjun Su
FLFenghua Liu
Fenghua Liu
STUDY QUESTION: What is the optimal timing of progesterone exposure to achieve live births for day-6 blastocysts in artificial frozen-thawed embryo transfer (FET) cycles? SUMMARY ANSWER: Live birth rates (LBRs) were comparable between day-6 and day-7 progesterone supplementation for day-6 blastocyst transfers in artificial FET cycles. WHAT IS KNOWN ALREADY: In artificial FET cycles, embryo–endometrium synchrony is primarily determined by the duration of progesterone exposure. Although blastocyst transfer is conventionally performed on day six of progesterone supplementation, the optimal duration of progesterone exposure remains uncertain. Available evidence suggests that the window of implantation may be relatively flexible for day-5 blastocysts, whereas day-6 blastocysts may have a distinct and potentially narrower window of implantation. However, prospective data evaluating different durations of progesterone exposure for blastocyst transfer—particularly for day-6 blastocysts—remain limited. STUDY DESIGN, SIZE, DURATION: This open-label randomized controlled trial (RCT) included 338 women undergoing FET in artificial cycles who had exclusively day-6 blastocysts available for transfer at enrolment. These blastocysts originated either from IVF/ICSI cycles with exclusive day-6 blastocyst formation or from previous embryo transfer attempts in which only day-6 blastocysts remained cryopreserved. Participants were randomized prior to progesterone initiation to undergo blastocyst transfer on 6 or 7 days of progesterone supplementation. Recruitment occurred between September 2022 and May 2024, with final follow-up completed in March 2025. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 338 participants were randomized equally to undergo blastocyst transfer on either Day 6 or Day 7 of progesterone supplementation. The primary outcome was LBR. Secondary outcomes included singleton and twin LBR, biochemical and clinical pregnancy, pregnancy loss, good birth outcome, and maternal and neonatal outcomes. The primary analysis followed the intention-to-treat (ITT) principle, with a per-protocol (PP) analysis also performed. Post hoc analyses included multivariable regression and subgroup analyses. MAIN RESULTS AND THE ROLE OF CHANCE: In the ITT analysis, the LBR was 45.0% (76/169) in the day-6 progesterone group and 40.2% (68/169) in the day-7 group (absolute difference, −4.7% [95% CI, −15.3% to 5.8%]; adjusted relative ratio (RR), 0.90 [95% CI, 0.70–1.14], P = 0.367). Rates of biochemical pregnancy, clinical pregnancy, pregnancy loss, and good birth outcome were comparable between groups. No differences were observed in maternal and neonatal outcomes. PP analysis yielded results consistent with the ITT analysis. Exploratory post hoc subgroup analyses identified a significant interaction between blastocyst expansion stage and treatment group (P for interaction = 0.004). Among early blastocyst transfers, the LBR was significantly lower in the day-7 progesterone group compared with the day-6 group (36.8% vs 53.8%; absolute difference, −17.1% [95% CI, −30.3% to −3.8%]; adjusted RR, 0.69 [95% CI, 0.51–0.94], P = 0.018). In contrast, among late blastocyst transfers, the LBR tended to be higher in the day-7 group (46.8% vs 31.7%; absolute difference, 15.0% [95% CI, −1.9% to 32.0%]; adjusted RR, 1.47 [95% CI, 0.95–2.28], P = 0.082), although this difference did not reach statistical significance. LIMITATIONS, REASONS FOR CAUTION: This study was open-label, which may have introduced performance bias; however, embryologists were blinded to group allocation, and all outcomes were objective, minimizing the risk of detection bias. Subgroup analyses were conducted post hoc, and the sample size may have been insufficient to detect differences within these subgroups. Accordingly, these findings should be interpreted with caution. In addition, the study was not powered to assess potential differences in treatment effects among specific subpopulations, such as patients with polycystic ovary syndrome, endometriosis, or repeated implantation failure. WIDER IMPLICATIONS OF THE FINDINGS: Based on this trial, LBRs were comparable between transfers performed on six versus seven days of progesterone exposure for day-6 blastocysts in artificial FET cycles. Exploratory subgroup findings, including those related to blastocyst expansion stage, are hypothesis-generating and require confirmation in future adequately powered RCTs. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by the Natural Science Foundation of Guangdong Province, China (2025A1515010073). No conflicts of interest are declared for all authors. TRIAL REGISTRATION NUMBER: Chinese Clinical Trial Registry (No. ChiCTR2200062901). URL: https://www.chictr.org.cn/bin/project/edit?pid=175020. TRIAL REGISTRATION DATE: 23 August 2022. DATE OF FIRST PATIENT’S ENROLMENT: 12 September 2022.